The Latest Cardiac and Vascular News
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, announced the 12-month results of the DETOUR 2 trial during a late-breaking clinical trial session at the 2022 VIVA Vascular InterVentional Advances (VIVA) […]
The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies […]
The Endologix ALTO Stent Graft System treats abdominal aortic aneurysms (AAA) with a success rate of 96.7% at 12 months as observed in ELEVATE IDE Study IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment […]
FDA to Review First-of-Its-Kind Percutaneous Femoropopliteal Bypass System IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, today announced the submission of a Premarket Approval (PMA) application requesting approval for the DETOUR System to […]
The AFX2 System integrates anatomical fixation into aortic endografts with an advanced delivery system to treat patients with abdominal aortic aneurysm (AAA). IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, announced that is has received […]
The DETOUR 2 study is a prospective, single-arm, international, multi-center clinical evaluation of the novel DETOUR™ System for fully percutaneous femoropopliteal bypass procedures. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, recently announced the 12-month […]
Minimally invasive procedure decreases recovery time and demonstrates new opportunities in outpatient care LEOMINSTER, Mass.–(BUSINESS WIRE)–The Vascular Care Group (TVCG), a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, today announced Stephen J. Hoenig M.D. successfully completed a percutaneous femoral-popliteal artery bypass at the Leominster, Mass. […]
The TORUS 2 study is a prospective, single-arm trial of 188 patients to evaluate safety and effectiveness of the TORUS Stent Graft System in the treatment of PAD in the SFA and proximal popliteal arteries IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ […]
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease, announced today the appointment of Dr. Matthew Thompson, as President and Chief Executive Officer. Dr. Thompson will also join Endologix’s Board of Directors. […]
JAGUAR Study Evaluates ALTO Compared to Other Commercially Available EVAR Devices IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a leader in the treatment of vascular disease, today announced that the first patient has been enrolled in the company’s JAGUAR study to compare outcomes for the company’s ALTO® Abdominal Stent Graft System to other commercially […]
